Entry Point Capital, LLC Arbutus Biopharma Corp Transaction History
Entry Point Capital, LLC
- $246 Million
- Q3 2025
A detailed history of Entry Point Capital, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Entry Point Capital, LLC holds 28,864 shares of ABUS stock, worth $130,465. This represents 0.05% of its overall portfolio holdings.
Number of Shares
28,864
Previous 61,105
52.76%
Holding current value
$130,465
Previous $188,000
30.32%
% of portfolio
0.05%
Previous 0.1%
Shares
3 transactions
Others Institutions Holding ABUS
# of Institutions
194Shares Held
118MCall Options Held
2.67MPut Options Held
693K-
Morgan Stanley New York, NY24.5MShares$111 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$60.3 Million22.38% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$52.2 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY11MShares$49.7 Million0.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.99MShares$40.6 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $678M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...